Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer:: analysis of 5732 Japanese subjects

被引:87
作者
Yamaji, Y
Mitsushima, T
Ikuma, H
Okamoto, M
Yoshida, H
Kawabe, T
Shiratori, Y
Saito, K
Yokouchi, K
Omata, M
机构
[1] Univ Tokyo, Fac Med, Dept Internal Med 2, Div Gastroenterol,Bunkyo Ku, Tokyo 1138655, Japan
[2] Kameda Gen Hosp, Dept Gastroenterol, Kamogawa, Japan
[3] Makuhari Clin, Chiba, Japan
关键词
D O I
10.1136/gut.49.3.335
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background-The relationship between Helicobacter pylori and reflux oesophagitis remains controversial. Aims-To evaluate the relationship between H pylori and reflux oesophagitis in a large number of Japanese subjects. Subjects-A total of 5732 consecutive Japanese subjects during a health screening were enrolled. Methods-Gastrointestinal endoscopy was performed on all subjects. We simultaneously measured serum anti-H pylori antibody and pepsinogen as markers of H pylori infection together with gastric atrophy. The risk of reflux oesophagitis was evaluated in relation to these markers, and the results were compared with those of gastric cancer. Results-Reflux oesophagitis was found in 108 subjects. Both positivity for H pylori antibody (adjusted odds ratio (OR) 0.67 (95% confidence interval 0.45-1.0)) and "low" pepsinogen indicating gastric atrophy (OR 0.35 (0.18-0.68)) were negatively associated with reflux oesophagitis. After subjects were classified into four groups based on positivity or negativity for H pylori antibody and "low" pepsinogen, the prevalence of reflux oesophagitis showed a decreasing trend as H pylori induced gastric atrophy became more severe. The risk of gastric cancer showed an increasing trend, exactly the opposite to that of reflux oesophagitis. Conclusions-Analysis of a large series of Japanese subjects revealed a decreasing prevalence of reflux oesophagitis in conjunction with progress of gastric atrophy induced by H pylori infection. This pattern was completely opposite to that of gastric cancer cases. A protective role of H pylori for reflux oesophagitis through the development of gastric atrophy has been suggested.
引用
收藏
页码:335 / 340
页数:6
相关论文
共 58 条
[1]   HELICOBACTER-PYLORI IN 205 CONSECUTIVE ENDOSCOPY PATIENTS [J].
BEFRITS, R ;
GRANSTROM, M ;
RYLANDER, M ;
RUBIO, C .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1993, 25 (02) :185-191
[2]   Not all Helicobacter pylori strains are created equal: Should all be eliminated? [J].
Blaser, MJ .
LANCET, 1997, 349 (9057) :1020-1022
[3]  
BLASER MJ, 1995, CANCER RES, V55, P2111
[4]  
BLASER MJ, 1993, EUR J GASTR HEPAT S1, V5, P99
[5]   RISING INCIDENCE OF ADENOCARCINOMA OF THE ESOPHAGUS AND GASTRIC CARDIA [J].
BLOT, WJ ;
DEVESA, SS ;
KNELLER, RW ;
FRAUMENI, JF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (10) :1287-1289
[6]   TREATMENT OF ULCERATIVE REFLUX ESOPHAGITIS WITH COLLOIDAL BISMUTH SUBCITRATE IN COMBINATION WITH CIMETIDINE [J].
BORKENT, MV ;
BEKER, JA .
GUT, 1988, 29 (03) :385-389
[7]   The course of symptoms after eradication of Helicobacter pylori (Hp):: A one-year follow-up of a cohort of 258 patients with duodenal ulcer (DU) or nonulcer dyspepsia (NUD). [J].
Bretagne, JF ;
Caekaert, A ;
Barthélémy, P ;
Hepysode .
GASTROENTEROLOGY, 1998, 114 (04) :A81-A81
[8]   PREVALENCE OF CAMPYLOBACTER-PYLORI IN ESOPHAGITIS, GASTRITIS, AND DUODENAL DISEASE [J].
CHENG, EH ;
BERMANSKI, P ;
SILVERSMITH, M ;
VALENSTEIN, P ;
KAWANISHI, H .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (06) :1373-1375
[9]  
Ching CK, 1996, AM J GASTROENTEROL, V91, P949
[10]  
Chow WH, 1998, CANCER RES, V58, P588